A Phase II Single Arm Study Assessing Efficacy & Safety of Nivolumab Plus Ipilimumab in Nonresectable/Metastatic Sarcoma and Endometrial Carcinoma Patients With Somatic Deficient MMR as a Selection Tool
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Endometrial cancer; Osteosarcoma; Sarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 18 Oct 2017 Planned initiation date changed from 1 Jan 2017 to 1 Dec 2017.
- 08 Dec 2016 New trial record